Supernus Pharmaceuticals (SUPN) said Monday the US Food and Drug Administration has cleared a label update for qelbree, a treatment for attention-deficit/hyperactivity disorder, or ADHD.
The updated label describes the drug's "partial agonist activity at the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter," which highlights the treatment's "multimodal pharmacodynamic profile," the biopharmaceutical company said.
The revised label also includes new lactation data for breastfeeding women with ADHD "showing that the transfer of Qelbree into breastmilk is low," Supernus said.
The drug is approved for use by people ages 6 years and older with ADHD, the company said.
SUPN shares were up 1.8% in early trading.
Price: 38.85, Change: +0.30, Percent Change: +0.78
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。